China's drug regulator approved a quadrivalent influenza virus split vaccine made by Liaoning Chengda Biotechnology (SHA:688739) subsidiary Chengda Biotechnology (Benxi), according to a Wednesday bourse filing in Shanghai.
The flu vaccine contains 15 micrograms of hemagglutinin from each influenza virus strain in every 0.5 milliliter dose.